S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Repare Therapeutics Stock Forecast, Price & News

-0.07 (-0.31%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
140,466 shs
Average Volume
170,682 shs
Market Capitalization
$947.80 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Repare Therapeutics logo

About Repare Therapeutics

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.


Repare Therapeutics (NASDAQ:RPTX) Shares Up 12.6%
December 7, 2021 |  americanbankingnews.com
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $22.04
December 3, 2021 |  americanbankingnews.com
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Up to $20.29
December 2, 2021 |  americanbankingnews.com
Repare Therapeutics (NASDAQ:RPTX) Shares Down 5%
November 29, 2021 |  americanbankingnews.com
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $26.46
November 24, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$140 thousand
Book Value
$5.23 per share


Net Income
$-53.42 million
Net Margins
Pretax Margin




Free Float
Market Cap
$947.80 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.70 out of 5 stars

Medical Sector

51st out of 1,394 stocks

Pharmaceutical Preparations Industry

16th out of 674 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -

Repare Therapeutics (NASDAQ:RPTX) Frequently Asked Questions

Is Repare Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Repare Therapeutics stock.
View analyst ratings for Repare Therapeutics
or view top-rated stocks.

When is Repare Therapeutics' next earnings date?

Repare Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Repare Therapeutics

How were Repare Therapeutics' earnings last quarter?

Repare Therapeutics Inc. (NASDAQ:RPTX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.83) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.12. The firm earned $0.28 million during the quarter, compared to analysts' expectations of $0.20 million. Repare Therapeutics had a negative net margin of 10,941.61% and a negative trailing twelve-month return on equity of 36.89%.
View Repare Therapeutics' earnings history

What price target have analysts set for RPTX?

7 brokerages have issued twelve-month target prices for Repare Therapeutics' shares. Their forecasts range from $45.00 to $54.00. On average, they expect Repare Therapeutics' share price to reach $48.43 in the next year. This suggests a possible upside of 113.2% from the stock's current price.
View analysts' price targets for Repare Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Repare Therapeutics' key executives?

Repare Therapeutics' management team includes the following people:
  • Mr. Lloyd Mitchell Segal, Pres, CEO & Director (Age 57, Pay $878.37k) (LinkedIn Profile)
  • Dr. Michael Zinda Ph.D., Exec. VP & Chief Scientific Officer (Age 50, Pay $585.85k)
  • Dr. Maria Koehler M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 64, Pay $625.02k)
  • Dr. Daniel Durocher Ph.D., Co-Founder
  • Dr. Frank Sicheri Ph.D., Co-Founder
  • Dr. Agnel Sfeir Ph.D., Co-Founder
  • Mr. Steve Forte, Exec. VP & CFO (Age 42)
  • Dr. Kim A. Seth, Exec. VP and Head of Bus. & Corp. Devel.
  • Mr. Cameron Black, Exec. VP of Discovery
  • Dr. Laurence F. Akiyoshi Ed.D., Exec. Vice-Pres of Organizational & Leadership Devel.

What other stocks do shareholders of Repare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), (NCLH), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AmerisourceBergen (ABC), AES (AES), Autodesk (ADSK) and (APA).

When did Repare Therapeutics IPO?

(RPTX) raised $126 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler served as the underwriters for the IPO.

What is Repare Therapeutics' stock symbol?

Repare Therapeutics trades on the NASDAQ under the ticker symbol "RPTX."

Who are Repare Therapeutics' major shareholders?

Repare Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include MPM Asset Management LLC (6.04%), CHI Advisors LLC (6.02%), BioImpact Capital LLC (4.42%), Sectoral Asset Management Inc (1.39%), BlackRock Inc. (1.15%) and Franklin Resources Inc. (0.80%). Company insiders that own Repare Therapeutics stock include Ansbert Gadicke, David P Bonita, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Thomas Civik and Todd Foley.
View institutional ownership trends for Repare Therapeutics

Which institutional investors are selling Repare Therapeutics stock?

RPTX stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, CHI Advisors LLC, Clough Capital Partners L P, Morgan Stanley, BioImpact Capital LLC, MPM Asset Management LLC, Goldman Sachs Group Inc., and Renaissance Technologies LLC. Company insiders that have sold Repare Therapeutics company stock in the last year include Ansbert Gadicke, David P Bonita, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, and Todd Foley.
View insider buying and selling activity for Repare Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Repare Therapeutics stock?

RPTX stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, Sectoral Asset Management Inc, Point72 Asset Management L.P., Dimensional Fund Advisors LP, HighVista Strategies LLC, SG Americas Securities LLC, and Trexquant Investment LP.
View insider buying and selling activity for Repare Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Repare Therapeutics?

Shares of RPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repare Therapeutics' stock price today?

One share of RPTX stock can currently be purchased for approximately $22.71.

How much money does Repare Therapeutics make?

Repare Therapeutics has a market capitalization of $947.80 million and generates $140 thousand in revenue each year. The company earns $-53.42 million in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does Repare Therapeutics have?

Repare Therapeutics employs 102 workers across the globe.

What is Repare Therapeutics' official website?

The official website for Repare Therapeutics is www.reparerx.com.

Where are Repare Therapeutics' headquarters?

Repare Therapeutics is headquartered at 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1.

How can I contact Repare Therapeutics?

Repare Therapeutics' mailing address is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. The company can be reached via phone at 857-412-7018 or via email at [email protected].

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.